Life sciences company Revive Therapeutics Ltd. (OTCQB: RVVTF) raised funds to treat infectious diseases and rare disorders, including meth addiction.

The company closed a private placement deal — with the original offer extended to Quebec-based investors — issuing more than 28.6 million units at a price of $0.11 (CA$0.15) per unit.

Total gross proceeds are roughly $3.2 million (CA$4.3 million).

See Also: Psychedelics Move …

Full story available on Benzinga.com